Drug Profile
Atacicept - Merck Serono
Alternative Names: Anti-Blys/anti-APRIL fusion protein; BLyS/APRIL-heterotrimers; TACI-IgLatest Information Update: 02 Feb 2024
Price :
$50
*
At a glance
- Originator ZymoGenetics
- Developer EMD Serono; Merck Serono; Vera Therapeutics; ZymoGenetics
- Class Antineoplastics; Antirheumatics; Recombinant fusion proteins; Urologics
- Mechanism of Action B cell activating factor inhibitors; Tumour necrosis factor ligand superfamily member 13 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III IgA nephropathy; Lupus nephritis
- Phase II/III Systemic lupus erythematosus
- Discontinued Chronic lymphocytic leukaemia; Multiple myeloma; Multiple sclerosis; Non-Hodgkin's lymphoma; Rheumatoid arthritis
Most Recent Events
- 25 Jan 2024 Efficacy and adverse events data from the phase IIb ORIGIN trial in IgA nephropathy released by Vera Therapeutics
- 05 Jul 2023 Vera Therapeutics suspends phase III trial due to financial reasons in Lupus nephritis (In adults, In the elderly) in USA (SC) (NCT05609812)
- 17 Jun 2023 Efficacy and adverse events data from the phase IIb ORIGIN trial in IgA nephropathy released by Vera Therapeutics